Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 2/20 | 0.35 |
| ▸ | GPR39 | O43194 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451880 | 0.74 | TACR3 (0.45) | CYP2C9TACR3 | |
| SCHEMBL454669 | 0.72 | SQOR (0.41) | CYP2C9TACR3 | |
| SCHEMBL347680 | 0.72 | DGAT2 (0.55) | DGAT2CYP2C9P2RX3WDR5PPARG | |
| SCHEMBL2261464 | 0.68 | CYP2C9 (0.52) | DGAT2CYP2C9P2RX3WDR5 | |
| SCHEMBL13092889 | 0.68 | P2RX3 (0.65) | DGAT2CYP2C9P2RX3WDR5PHGDH | |
| SCHEMBL451719 | 0.68 | P2RX3 (0.47) | CYP2C9P2RX3PPARGPHGDHIDO1 | |
| SCHEMBL16504274 | 0.67 | P2RX3 (0.63) | DGAT2CYP2C9P2RX3WDR5CNR2 | |
| SCHEMBL2263089 | 0.67 | CYP2C9 (0.52) | DGAT2CYP2C9P2RX3WDR5 | |
| SCHEMBL3070767 | 0.67 | P2RX3 (0.64) | DGAT2CYP2C9P2RX3WDR5PHGDH | |
| SCHEMBL3070764 | 0.67 | P2RX3 (0.64) | DGAT2CYP2C9P2RX3WDR5PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | DGAT2 3948/4885CYP2C9 4126/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.